CalciMedica Inc.
01/28/2026 | Press release | Distributed by Public on 01/28/2026 16:29
Material Event (Form 8-K)
| Item 8.01. |
Other Events. |
On January 28, 2026, CalciMedica, Inc. (the "Company") announced the discontinuation of its Phase 2 KOURAGE clinical trial following a recommendation from the trial's Independent Data Monitoring Committee.
In connection with the discontinuation of the KOURAGE trial and the resulting reduction in planned operating expenses, the Company is updating its financial guidance. The Company now expects that its existing cash, cash equivalents, and short-term investments will be sufficient to fund its current operating plan into the fourth quarter of 2026, compared to its previously disclosed guidance of the second half of 2026.
CalciMedica Inc. published this content on January 28, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on January 28, 2026 at 22:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]